Trial Profile
An Investigator-Initiated Study To Evaluate Ara-C and Idarubicin in Combination with the Selective Inhibitor Of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Relapsed Or Refractory AML
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2023
Price :
$35
*
At a glance
- Drugs Selinexor (Primary) ; Cytarabine; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms SAIL
- 01 Feb 2023 Results of exploratory analysis (n=15) assessing the clonal response patterns in patients with relapsed/refractory acute myeloid leukemia treated with selinexor in a phase II (SAIL) trial, published in the Annals of Hematology.
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 16 May 2019 According to a Karyopharm Therapeutics Media Release, data from this trial will be presented at the upcoming European Hematology Association 2019 Annual Meeting.